Florida is currently home to 3772 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Urological Research Network, Hialeah, Florida
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Recruiting
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally) and 8 to \<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/22/2025
Locations: University of South Florida Morsani Center for Advanced Healthcare, Tampa, Florida
Conditions: Myasthenia Gravis
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Recruiting
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethni... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Amyloidosis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Recruiting
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Multiple Myeloma
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Recruiting
The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Florida Health, Gainesville, Florida
Conditions: Solid Tumors
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
05/22/2025
Locations: JEM Research Institute, Atlantis, Florida
Conditions: Alzheimer Disease
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Bay Pines VA Healthcare System, Bay Pines, Florida
Conditions: Arthritis, Psoriatic
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Recruiting
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic Hospital, Jacksonville, Florida
Conditions: Advanced Solid Tumor
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Recruiting
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/22/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/22/2025
Locations: UHealth Diabetes Research Institute, Miami, Florida
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Neurostimulation for Treatment of Chronic Upper Limb Pain After Brachial Plexus Injury
Recruiting
The purpose of this study is to see how much pain intensity is affected by high frequency spinal cord stimulation therapy in individuals with serious brachial plexus injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Brachial Plexus Injury
GDNF Gene Therapy for Multiple System Atrophy
Recruiting
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
05/22/2025
Locations: Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida
Conditions: Multiple System Atrophy